<DOC>
	<DOCNO>NCT02141854</DOCNO>
	<brief_summary>Study drug placebo supply Teva multidose dry powder inhaler ( MDPI ) device provide participant use home . Participants perform spirometry every visit . Each participant give diary visit use next visit . Rescue medication ( albuterol/salbutamol ) dispense visit , need , determine investigational center personnel .</brief_summary>
	<brief_title>Efficacy Safety Study FP MDPI Compared With FS MDPI Adolescent Adult Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Best prebronchodilator FEV1 40 85 % predict normal value . 2 . Current Asthma Therapy : Patients must shortacting Î²2agonist ( rescue use ) minimum 8 week Screening Visit ( SV ) qualify dose inhale corticosteroid ( ICS ) . The ICS may either ICS monotherapy ICS/longacting beta agonist ( LABA ) combination . The ICS component patient 's asthma therapy stable minimum 1 month provide consent . 3 . Reversibility Disease : Patients must least 15 % reversibility ( patient ) least 200 mL increase baseline FEV1 ( patient age 18 older ) within 30 minute 2 4 inhalation albuterol/salbutamol SV . Note : Patients qualify study due failure meet reversibility permit perform retest within 7 day . 4 . Patients must provide write informed consent/assent.. For minor patient ( age 12 17 year , applicable per local regulation ) , write ICF must sign dated parent/legal guardian write assent form must sign dated patient ( applicable ) . Note : Age requirement specify local regulation . 5 . Outpatient &gt; = 12 year age date consent/assent . In country local regulation permit enrollment adult patient , patient must 18 year age old . 6 . Asthma diagnosis : The patient diagnosis asthma define NIH . The asthma diagnosis present minimum 3 month stable ( defined exacerbation change asthma medication ) least 30 day . 7 . The patient able perform acceptable repeatable spirometry . 8 . The patient able perform PEF handheld peak flow meter . 9 . The patient able use MDI device without spacer device MDPI device . 10 . The patient able withhold ( judged investigator ) regimen ICS study drug , rescue medication least 6 hour SV treatment visit . 11 . The patient/parent/legal guardian/caregiver capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement . 12 . SABAs : All patient must able replace current SABA albuterol/salbutamol HFA MDI inhalation aerosol duration study . 13 . Female patient may pregnant , breastfeed , attempt become pregnant . criterion may apply , please contact investigator information 1 . A history lifethreatening asthma exacerbation ( asthma episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure ) . 2 . The patient pregnant lactating , plan become pregnant study period 30 day study . 3 . The patient participate randomized patient investigational drug study within 30 day SV . 4 . The patient previously participate randomized patient study Fp MDPI FS MDPI . 5 . The patient know hypersensitivity corticosteroid , salmeterol , excipients study drug rescue medication formulation ( ie , lactose ) . 6 . The patient treat know strong cytochrome P450 ( CYP ) 3A4 inhibitor ( eg , azole antifungal , ritonavir , clarithromycin ) within 30 day SV . 7 . The patient treat prohibited medication prescribe ( per protocol ) washout period SV . 8 . The patient currently smoke smoke history 10 pack year ( pack year define smoke 1 pack cigarettes/day 1 year ) . The patient must use tobacco product within past year ( eg , cigarette , cigar , chew tobacco , pipe tobacco ) . 9 . The patient culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve least 2 week SV . 10 . The patient history alcohol drug abuse within 2 year precede SV . 11 . The patient asthma exacerbation require systemic corticosteroid within 30 day SV , hospitalization asthma within 2 month SV . 12 . Initiation dose escalation immunotherapy ( administer route ) plan study period . However , patient stable immunotherapy may consider inclusion . 13 . The patient use immunosuppressive medication within 4 week SV . 14 . The patient unable tolerate unwilling comply appropriate washout period withhold applicable medication . 15 . The patient untreated oral candidiasis SV . Patients clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study . 16 . The patient history positive test human immunodeficiency virus ( HIV ) , active hepatitis B virus , hepatitis C infection . 17 . The patient either employee immediate relative employee clinical investigational center . 18 . A member patient 's household participate study time . However , enrol patient completes discontinues participation study , another patient household may screen . 19 . The patient disease/condition medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . criterion may apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>